Fed. Circ. Questions If Safer OxyContin Profits Came From IP

By Dani Kass · October 7, 2024, 9:39 PM EDT

An attorney for Purdue Pharma didn't seem to find much purchase at the Federal Circuit on Monday as he argued that the company's patents for abuse-deterrent OxyContin weren't obvious, claiming other...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Case Information

Case Title

Purdue Pharma L.P. v. Accord Healthcare, Inc.

Case Number

23-1953

Court

Appellate - Federal Circuit

Nature of Suit

835 Patent - (ANDA) (Fed. Qst.)

Date Filed

May 30, 2023

Featured Stories

End Of J&J Talc Unit's Ch. 11 Shows 'Texas Two-Step' Risks No Photo Available

Rick Archer

The recent dismissal of Johnson & Johnson's third try to spin off its talc liability into a new entity with a "Texas two-step" shows t... (more story)

J&J Ch. 11 Case Tossed, New Tariffs May Boost Bankruptcies No Photo Available

Yun Park

A Texas bankruptcy judge dismissed Johnson & Johnson's third attempt to settle cancer claims through Chapter 11, tossing Red River Tal... (more story)

Defamation Litigation Roundup: Jay-Z, Blake Lively, Drake No Photo Available

Theresa Schliep

In this month's review of ongoing defamation fights, Law360 looks back on an escalation in Jay-Z's case against personal injury lawyer... (more story)